Results 201 to 210 of about 128,630 (294)

Glucagon-like peptide 1 (GLP-1) [PDF]

Science-Business eXchange, 2012
openaire   +1 more source

Identification of MEF2A, MEF2C, and MEF2D interactomes in basal and Fsk‐stimulated mouse MA‐10 Leydig cells

Andrology, EarlyView.
Abstract Background Myocyte enhancer factor 2 transcription factors regulate essential transcriptional programs in various cell types. The activity of myocyte enhancer factor 2 factors is modulated through interactions with cofactors, chromatin remodelers, and other regulatory proteins, which are dependent on cell context and physiological state.
Karine de Mattos, Marie‐Pier Scott‐Boyer, Arnaud Droit, Robert S. Viger, Jacques J. Tremblay   +4 more
wiley   +1 more source

The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study. [PDF]

Ther Adv Musculoskelet Dis
Israel A, Hassan F, Merzon E, Kurtam J, Awad J, Assalia M, Green I, Vinker S, Naffaa ME.   +8 more
europepmc   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review. [PDF]

Cureus
Huang JXF, Wu J, Ahmad H, Li J, Joshi S, Yousaf A, Pemminati R, Pemminati S.   +7 more
europepmc   +1 more source

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP‐1 Receptor Agonist Therapy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To explore changes in body composition in adolescents with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and their association with metabolic syndrome (MetS) components. Methods This real‐world retrospective study included adolescents (12–18 years) with obesity who received multidisciplinary lifestyle‐based ...
Adar Lopez, Liat Perl, Eyal Cohen‐Sela, Ophir Borger, Yael Issan, Hagar Interator, Erez Azoulay, Hadar Moran‐Lev, Ronit Lubetzky, Shira Zelber‐Sagi, Yael Lebenthal, Avivit Brener   +11 more
wiley   +1 more source

Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review. [PDF]

Front Endocrinol (Lausanne)
Mirghani H, Albishi L, Alblewi SM.
europepmc   +1 more source

Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In this territory‐wide cohort study, improving glycemic control can be observed regardless of cirrhosis status. Oral antidiabetic medication was more often used in the non‐cirrhosis group, and insulin was preferred in patients with decompensated cirrhosis, who exhibited an increasing incidence of hypoglycemia over the years and need individualized ...
Mary Yue Wang, Sherlot Juan Song, Nana Peng, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jimmy Che‐To Lai, Terry Cheuk‐Fung Yip   +6 more
wiley   +1 more source

Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Rev Cardiovasc Med
West L, Patolia H, Chapman B, Laffin L, Vest AR, Sauer AJ, Martyn T.   +6 more
europepmc   +1 more source